Literature DB >> 2266162

The use of mifepristone prior to prostaglandin-induced mid-trimester abortion.

D R Urquhart1, A A Templeton.   

Abstract

It has previously been established that the administration of mifepristone prior to prostaglandin-induced second trimester termination of pregnancy significantly reduces the induction to abortion interval. In this study, mifepristone (600 mg) was administered 24, 36 and 48 h prior to extra-amniotic infusion of prostaglandin in an attempt to elucidate the optimal time interval. There was a significant reduction in the induction to abortion interval, dose of prostaglandin required and attendant side effects in all three treated groups compared to controls. However, there was no significant difference among the treatment groups, despite evidence of increased uterine activity 36 h following mifepristone administration. No bleeding was observed prior to prostaglandin infusion in any of the groups and it is suggested that mifepristone could be administered safely prior to hospital admission for termination.

Entities:  

Keywords:  Abortion, Induced; Biology; Control Groups; Demographic Factors; Developed Countries; Endocrine System; Europe; Examinations And Diagnoses; Family Planning; Fertility Control, Postconception; Hormone Antagonists; Hormones; Laboratory Examinations And Diagnoses; Northern Europe; Physiology; Population; Population Characteristics; Pregnancy; Pregnancy, Second Trimester; Prostaglandins--administraction and dosage; Reproduction; Research Methodology; Ru-486--administraction and dosage; Ru-486--side effects; United Kingdom

Mesh:

Substances:

Year:  1990        PMID: 2266162     DOI: 10.1093/oxfordjournals.humrep.a137203

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  3 in total

Review 1.  Mifepristone. Separating fact from fiction.

Authors:  R C Henshaw; A A Templeton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

Review 2.  Proven and potential clinical applications of mifpristone (RU486).

Authors:  Irving M Spitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 3.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.